IRIS
Daniele, Armenia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 59
NA - Nord America 6
Totale 65
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 59
US - Stati Uniti d'America 6
Totale 65
Salva come PNG Salva come JPEG
Città #
Rome 59
Santa Clara 4
Totale 63
Salva come PNG Salva come JPEG
Nome #
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 4
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 3
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 3
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 3
Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells 3
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 3
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 3
HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression 3
A high HBsAg genetic complexity can influence HBV immunogenicity in the setting of acute infection 2
Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors 2
P0580 : Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome 2
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 2
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBVcoinfected patients on first-line therapy 2
A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection. 2
Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study 2
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 2
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals. 2
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study 1
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 1
P696 A COMPLEX HBV QUASISPECIES IN RT AND HBsAg CHARACTERIZES PATIENTS WITH ACUTE HEPATITIS B: A REFINED UDPS ANALYSIS 1
Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance? 1
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors 1
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals 1
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 1
Emerging patterns and implications of HIV-1 integrase inhibitor resistance 1
HIV-1 INTEGRASE MUTATIONS, FOUND AS MINORITY QUASISPECIES IN PATIENTS NAIVE TO INTEGRASE INHIBITORS, ARE ASSOCIATED WITH DECREASED SUSCEPTIBILITY TO RALTEGRAVIR AND ELVITEGRAVIR IN VITRO 1
ANTI-HIV-1 ACTIVITY OF NEW INTEGRASE INHIBITORS IN LYMPHOCYTES AND HUMAN PRIMARY MACROPHAGES 1
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 1
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 1
Hepatitis B Surface Antigen Genetic Elements Critical for Immune Escape Correlate With Hepatitis B Virus Reactivation Upon Immunosuppression 1
Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors 1
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 1
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 1
P681 HBsAg MUTATIONS WITH ENHANCED CAPABILITY TO EVADE IMMUNE RESPONSE ARE ASSOCIATED WITH HBV REACTIVATION DURING IMMUNOSUPPRESSION 1
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice 1
Impact of baseline HIV-1 integrase polymorphisms on virological outcome in a large European cohort of patients starting a raltegravir-containing regimen 1
Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens 1
P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing 1
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 1
HIV MDR is still a relevant issue despite its dramatic drop over the years 1
A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naive Patients Starting a First-Line HAART 1
Darunavir (DRV)/r plus raltegravir (RAL) dual regimen in multi-experienced population: long term efficacy and tolerability 1
Totale 68
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20242 0 0 0 0 0 0 0 0 0 0 0 2
2024/202566 55 0 11 0 0 0 0 0 0 0 0 0
Totale 68